News

"Our outstanding researchers at the University of Kentucky are leading the way in translational chemical biology, and the recently awarded COBRE grant is a testament to UK CPRI’s success in their constant pursuit of discovery," said UK President Eli Capilouto.

Researchers will be looking at a medication that recently received experimental approval from the USDA and its impact on the newly characterized form of dementia known as LATE. LATE is a disease with symptoms similar to Alzheimer’s disease.

KYNETIC, funded by the National Institutes of Health (NIH), is excited to announce that five of the seven projects recently awarded $50,000 to bring their innovations toward product development are from the University of Kentucky.

The National Institutes of Health award will fund ongoing research led by UK Neuroscience and Spinal Cord and Brain Injury Research Center (SCoBIRC) Professor Patrick Sullivan, Ph.D., who has studied the effects of the experimental drug MP201 on TBI.

This work is looking at a study medication, BAN2401, to determine if it can help prevent worsening memory and thinking among individuals who might be at risk for future decline. They are hoping it will ultimately help prevent Alzheimer’s disease.

A group of UK professors and scientists efforts to identify possible direct therapeutic approaches to treat COVID-19 was published in the Perspectives section of the most recent issue of Science, a journal of the American Association for the Advancement of Science (AAAS).

A new study led by UK researcher April Young and Emory researcher Hannah Cooper shows that a number of pharmacies in the Appalachian region of Kentucky are limiting the dispensing of buprenorphine, a medication used to treat opioid use disorder (OUD).

“I am continually impressed and grateful every day for the effort and dedication of the staff of UK Healthcare’s clinical laboratories. They are in the lab working to improve the lives of patients 24/7 throughout the year.

Linda J. Van Eldik, director of the Sanders-Brown Center on Aging at UK, co-authored a paper reporting the first human clinical study of a drug candidate that suppresses injury and disease-induced inflammation of the brain.

According to the World Health Organization (WHO) every two minutes a child dies of malaria and each year, more than 200 million new cases of the disease are reported. For the last 15 years, Kip Guy, dean of UK’s College of Pharmacy, has worked with a team of researchers to develop an anti-malarial drug.